CN120435467A - 补体因子b抑制剂及其药物组合物和应用 - Google Patents

补体因子b抑制剂及其药物组合物和应用

Info

Publication number
CN120435467A
CN120435467A CN202380089703.3A CN202380089703A CN120435467A CN 120435467 A CN120435467 A CN 120435467A CN 202380089703 A CN202380089703 A CN 202380089703A CN 120435467 A CN120435467 A CN 120435467A
Authority
CN
China
Prior art keywords
alkyl
alkylene
cycloalkyl
optionally substituted
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380089703.3A
Other languages
English (en)
Chinese (zh)
Inventor
谷正松
吉范阳
邵顺杰
周媛
陈照强
屈孟杨
白璐
骆洁
方磊
陈斌
王绍晖
张佩宇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhuhai United Laboratories Co Ltd
Original Assignee
Zhuhai United Laboratories Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhuhai United Laboratories Co Ltd filed Critical Zhuhai United Laboratories Co Ltd
Publication of CN120435467A publication Critical patent/CN120435467A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202380089703.3A 2022-12-31 2023-12-29 补体因子b抑制剂及其药物组合物和应用 Pending CN120435467A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202211737515 2022-12-31
CN202211737515.0 2022-12-31
CN202310699631 2023-06-13
CN202310699631.6 2023-06-13
PCT/CN2023/143205 WO2024141011A1 (zh) 2022-12-31 2023-12-29 补体因子b抑制剂及其药物组合物和应用

Publications (1)

Publication Number Publication Date
CN120435467A true CN120435467A (zh) 2025-08-05

Family

ID=91716537

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380089703.3A Pending CN120435467A (zh) 2022-12-31 2023-12-29 补体因子b抑制剂及其药物组合物和应用

Country Status (3)

Country Link
JP (1) JP2026502231A (cg-RX-API-DMAC7.html)
CN (1) CN120435467A (cg-RX-API-DMAC7.html)
WO (1) WO2024141011A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026002007A1 (zh) * 2024-06-25 2026-01-02 珠海联邦制药股份有限公司 补体因子b抑制剂及其药物组合物和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8653099B2 (en) * 2008-08-19 2014-02-18 Janssen Pharmaceutica Cold menthol receptor antagonists
CN103402996B (zh) * 2011-01-04 2015-02-11 诺瓦提斯公司 可用于治疗年龄相关性黄斑变性(amd)的吲哚化合物或其类似物
WO2012135697A2 (en) * 2011-03-30 2012-10-04 H. Lee Moffitt Cancer Center & Research Institute Inc. Novel rho kinase inhibitors and methods of use
CN104040422B (zh) * 2012-02-29 2016-04-13 宝理塑料株式会社 照相机模块用液晶性树脂组合物
SG11201406973PA (en) * 2012-05-04 2014-12-30 Novartis Ag Complement pathway modulators and uses thereof
JO3425B1 (ar) * 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
WO2016077240A2 (en) * 2014-11-10 2016-05-19 Forge Life Science, Llc Anti-hcmv compositions and methods
HRP20251596T1 (hr) * 2017-08-31 2026-01-30 Novartis Ag Nove upotrebe derivata piperidinil-indola
KR20230049115A (ko) * 2020-08-07 2023-04-12 상하이 메이유에 바이오테크 디벨롭먼트 컴퍼니 리미티드 보체 인자 b 억제제 및 이의 약학적 조성물, 제조 방법 및 용도

Also Published As

Publication number Publication date
WO2024141011A1 (zh) 2024-07-04
JP2026502231A (ja) 2026-01-21

Similar Documents

Publication Publication Date Title
JP7641388B2 (ja) 一連のピペリジン置換安息香酸系化合物及びその使用
JP7664947B2 (ja) Ｉｌ－１７の調節因子としてのイミダゾリダジン
JP6805220B2 (ja) 治療上活性な化合物およびそれらの使用方法
CN102906091B (zh) 苦参酸/碱衍生物及其制备方法和用途
JP7187575B2 (ja) Ｒｈｏキナーゼ阻害剤としてのベンゾピラゾール系化合物
TWI864071B (zh) 2-羥環烷-1-胺甲醯基衍生物
JP7333342B2 (ja) ２，３－ジヒドロ－１ｈ－ピロリジン－７－ホルムアミド誘導体およびその使用
JP7624924B2 (ja) ニトロキソリンプロドラッグ及びその使用
CA3078312A1 (en) Substituted fused tetra-cyclic 4-oxo-1,4-dihydropyridine derivatives and pharmaceutical compositions thereof useful for treatment of hbv
AU2017359025A1 (en) Cyclobutane- and azetidine-containing mono and spirocyclic compounds as alpha V integrin inhibitors
JP7207634B2 (ja) Ｐ２ｘ３及び／又はｐ２ｘ２／３受容体アンタゴニスト、それを含む医薬組成物及びその使用
CN104822680A (zh) 咪唑并吡啶化合物
CN117715906A (zh) 胰高血糖素样肽-1受体调节剂及其用途
CN120225506A (zh) 桥环并哒嗪类化合物及其用途
CN114206893A (zh) (杂)芳基-甲基-硫代-β-D-吡喃半乳糖苷衍生物
TWI782523B (zh) 用作ret激酶抑制劑的化合物及其應用
JP2023539275A (ja) 新規なｒｈｏ関連タンパク質キナーゼ阻害剤の調製方法およびその調製方法における中間体
CN105085383A (zh) 5-甲基-2(1h)吡啶酮衍生物及其制备方法和用途
JP2025520541A (ja) コロナウイルス感染症の治療のための化合物
CN120424053A (zh) Gpr75配体20-hete生成抑制剂
CN105524053A (zh) 四氢苯并噻吩化合物
TW202233575A (zh) 用於治療與lpa受體活性相關的病狀的化合物及組合物
JP2026503938A (ja) Ｃｙｐ１１ａ１阻害剤化合物ならびにその調製方法およびその使用
JP2026502231A (ja) 補体因子ｂ阻害剤、その医薬組成物および使用
JP7358657B2 (ja) 抗ウイルス活性を有するアミド誘導体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination